Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
about
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidenceCombination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancerTreatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
P2860
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Management of castrate resista ...... ptimal sequence of treatments.
@en
Management of castrate resista ...... ptimal sequence of treatments.
@nl
type
label
Management of castrate resista ...... ptimal sequence of treatments.
@en
Management of castrate resista ...... ptimal sequence of treatments.
@nl
prefLabel
Management of castrate resista ...... ptimal sequence of treatments.
@en
Management of castrate resista ...... ptimal sequence of treatments.
@nl
P2093
P2860
P1476
Management of castrate resista ...... ptimal sequence of treatments.
@en
P2093
Giuseppe DiLorenzo
Guru Sonpavde
Joaquim Bellmunt
Neeraj Agarwal
Nicholas J Vogelzang
Tian Yi Zhang
P2860
P2888
P304
P356
10.1007/S11934-013-0322-0
P577
2013-06-01T00:00:00Z